Compare EH & ENGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EH | ENGN |
|---|---|---|
| Founded | 2014 | 1999 |
| Country | China | Canada |
| Employees | N/A | 82 |
| Industry | Military/Government/Technical | |
| Sector | Industrials | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 745.8M | 647.1M |
| IPO Year | 2019 | N/A |
| Metric | EH | ENGN |
|---|---|---|
| Price | $11.00 | $7.34 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 5 |
| Target Price | ★ $21.85 | $21.00 |
| AVG Volume (30 Days) | ★ 641.5K | 486.6K |
| Earning Date | 05-26-2026 | 03-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $33.23 | N/A |
| Revenue Next Year | $73.83 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.06 | $2.66 |
| 52 Week High | $20.44 | $12.25 |
| Indicator | EH | ENGN |
|---|---|---|
| Relative Strength Index (RSI) | 51.81 | 47.92 |
| Support Level | $9.06 | $6.04 |
| Resistance Level | $12.80 | $8.14 |
| Average True Range (ATR) | 0.52 | 0.53 |
| MACD | 0.16 | 0.15 |
| Stochastic Oscillator | 84.65 | 79.88 |
EHang Holdings Ltd is an urban air mobility (UAM) technology platform company. It focuses on making safe, autonomous, eco-friendly air mobility accessible to everyone. EHang provides customers in various industries with unmanned aerial vehicle (UAV) systems and solutions: air mobility (including passenger transportation and logistics), smart city management, and aerial media solutions. EHang's EH216-S has received a production certificate and standard airworthiness certificate for passenger-carrying pilotless eVTOL aircraft issued by the Civil Aviation Administration of China. The group continues to explore the boundaries of the sky to make flying technologies benefit life in smart cities.
enGene Holdings Inc is a clinical-stage biotechnology company mainstreaming genetic medicine through the delivery of therapeutics to mucosal tissues and other organs, with the goal of creating new ways to address diseases with high clinical needs, beginning with non-muscle invasive bladder cancer (NMIBC). The Company is developing non-viral gene therapies based on its novel and proprietary dually derived chitosan, or DDX, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs.